Small- and mid-cap biotechs are attracting healthy buying interest and setting off bullish divergences that support higher prices into year-end.
- Zacks•2 days ago
Supernus Pharmaceuticals, Inc. (SUPN) announced that the FDA has granted a tentative approval to the company's sNDA for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
- GlobeNewswire•5 days agoSupernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR® to Include Migraine Prophylaxis in Adults
ROCKVILLE, Md., Aug. 19, 2016-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
Supernus Pharmaceuticals, Inc. (SUPN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||22.09 x 200|
|Ask||22.12 x 400|
|Day's Range||22.03 - 23.18|
|52wk Range||9.51 - 24.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||45.12|
|Avg Vol (3m)||523,843|
|Dividend & Yield||N/A (N/A)|